The 9th Annual World ADC Awards took place on Thursday, September 8, 2022, as part of the 13th World ADC San Diego 2022. Ask the attendees, and they will tell you that it was a fantastic evening allowing the ADC community to recognize recent successes, and long-term commitment, and celebrate the success of those who have gone above and beyond to ensure continued success within this field.

The judges
Nearly 700 votes were cast, and many scientific proposals were put forward, all reviewed by our judging panel which included:

  • Ian Schwartz (Director, Bioconjugation Process Development at Exelixis),
  • Jagath Reddy Junutula (President & Chief Executive Officer of Aarvik Therapeutics),
  • John Lambert (Consultant, Attager Consulting),
  • Rakesh Dixit (President & CEO, Bionavigen) and
  • Robert Lutz (Chief Science Officer, Iksuda).

“The 2022 World ADC Awards was a special evening to celebrate individual and company successes, as well as the hard work that those across the field are doing on a daily basis. This year was particularly special as it was the first time since 2019 that we were able to come together in-person, and we were delighted to see the quality of research and caliber of nominations, mirroring the recent progress we are seeing across the entire industry right now!” noted Thomas Cosgrove, Program Director for World ADC San Diego.

The 2022 winners are:

Advertisement #3 
Best ADC Platform Technology
Winner – SynaffixRunner-Up – Catalent SMARTag  Technology

Best Contract Research (CRO) Provider

Winner – NJ Bio, IncRunner-Up – Abzena

Best Contract Manufacturing (CMO) Provider

Winner – BSP PharmaceuticalsRunner-Up – WuXi XDC

Best New Drug Developer

Winner – Iksuda TherapeuticsRunner-Up – Exelixis

Most Promising Clinical Candidate

Winner – Mirvetuximab soravtansine, ImmunoGenRunner-Up – Patritumab deruxtecan, Daiichi Sankyo

Best ADC Pre-Clinical Publication 2021

Winner – Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Yamazaki CM, Yamaguchi A, Anami Y, Xiong W, Otani Y, Lee J, Ueno NT, Zhang N, An Z, Tsuchikama K. Nat Commun. 2021 Jun 10;12(1):3528. doi: 10.1038/s41467-021-23793-7. PMID: 34112795Runner-Up – The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models. Kendsersky NM, Lindsay J, Kolb EA, Smith MA, Teicher BA, Erickson SW, Earley EJ, Mosse YP, Martinez D, Pogoriler J, Krytska K, Patel K, Groff D, Tsang M, Ghilu S, Wang Y, Seaman S, Feng Y, Croix BS, Gorlick R, Kurmasheva R, Houghton PJ, Maris JM. Clin Cancer Res. 2021 May 15;27(10):2938-2946. doi: 10.1158/1078-0432.CCR-20-4221. Epub 2021 Feb 22. PMID: 33619171

Best ADC Pre-Clinical Publication 2021

WinnerSacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O’Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators. N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485. PMID: 33882206 Clinical Trial.Runner-Up Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Havenith K, Feingold J, He S, Qin Y, Ungar D, Zhang X, Carlo-Stella C.Lancet Oncol. 2021 Jun;22(6):790-800. doi: 10.1016/S1470-2045(21)00139-X. Epub 2021 May 11. PMID: 33989558 Clinical Trial.

Best Poster 2022

GLK-33, novel anti-CD33 ADC with auristatin payload MMAU shows wide preclinical therapeutic window, and, Hydrophilic glycopeptide linker improves properties of auristatin, anthracycline and exatecan ADCs, Glykos

Outstanding Academic Investigator

Dhaval Shah, University at Buffalo, The State University of New York

The George R Pettit Individual Input to the Field Award 2021

Gilles Gallant, Daiichi Sankyo (now of Mythic Therapeutics)

Long Standing Contribution to the Field

Robert Lutz, Iksuda Therapeutics
Advertisement #4